semaglutide for obesity shreveport Landry vetoes weight-loss drug insurance coverage state employees, teachers Oral Wegovy Weight-Loss Treatment &

EPS: ~$23.50 Forward P/E: ~42 (premium justified by growth) PEG Ratio: ~0.9 (attractive given growth rate) Long-Term Track Record Performance: 52-Week Range: $623.78 - $999.92 1-Year Return: +20-25% (volatile but trending up) Market Leadership: Approaching $1 trillion valuation Dividend Profile: Current Yield: ~0.6% (modest but growing) Annual Dividend: $6.00 per share Growth Rate: Consistently increasing ~15% CAGR The dividend is small now, but management prioritizes reinvestment in R&D while rewarding long-term shareholders with steady increases

These findings align with those of Kim et al

Not all lipids provide protective effects from AMD [67, 68]

Obesity is also associated with higher rates of diabetes, which has wellknown consequences for pregnancy, and ovulatory dysfunction, which impacts fertility, such as in polycystic ovarian syndrome (PCOS)